Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories)-Global Forecast to 2025
[174 Pages Report] The global tissue diagnostic market size is expected to reach USD 4.7 billion by 2025 from USD 3.4 billion in 2020, at a CAGR of 6.5%. This industry is experiencing significant growth due to the rising incidence of cancer, developing infrastructure for cancer diagnosis, recommendation of cancer screening, availability of reimbursements, and increasing healthcare expenditure.
Consumables segment to dominate the tissue diagnostic market in 2019
Based on the product, the tissue diagnostics market is segmented into instruments and consumables. The consumables segment is expected to grow at the highest growth rate during the forecast period. This is attributed primarily to their requirement in large numbers, cost-effectiveness, and ease of use. The increasing number of reagent rental agreement is also one of the major factors to drive the growth of the consumables market globally
Immunohistochemistry segment to dominate the tissue diagnostic market in 2019
Based on the technology, the tissue diagnostic market is segmented into immunohistochemistry, in situ hybridization, digital pathology and workflow, and special staining. The immunohistochemistry segment is estimated to register the highest CAGR during the forecast period. This can primarily be attributed to the increasing prevalence of chronic diseases across the globe, where this technology is mostly used in tissue diagnostics.
North America was the largest regional market for tissue diagnostic in 2019
The tissue diagnostic market has been analyzed for North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America held the largest share of the market, followed by Europe. Easy accessibility to advanced technologies, government initiatives for screening cancer patients, favourable reimbursement scenario for pathology diagnostic tests, increasing healthcare expenditure, and high-quality infrastructure for hospitals and clinical laboratories in this region are the major factors driving the growth of the tissue diagnostic market in North America.
Key Market Players
The prominent players operating in the tissue diagnostic market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), ABCAM (UK), Merck KGAA (Germany), BD (US), Hologic (US), Bio Rad (US), Biomeriux (France), Sakura Fientek Japan (Japan), BioSB (US), Biogenex (US), Cell Signaling Technology (US), Histoline Laboratories (Italy), Slee Medical GMBH (Germany), Amos Scientific PTY Ltd (Australia), Jinhua Yidi Medical Appliance Co.Ltd (China), Medite GMBH (Germany), Cellpath Ltd(UK), and Dipath S.P.A. (Italy).
Roche (Switzerland) is one of the leading players in the tissue diagnostic market in 2019. The company offers a broad product portfolio across the globe. Over the years, the company has maintained its leading position in the market.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
20182025 |
|
Base year considered |
2018 |
|
Forecast period |
20202025 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product, Technology, Disease, End User, And Region |
|
Geographies covered |
North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and the RoE), APAC (China, Japan, India, RoAPAC), Rest of the World (Latin America and Middle East & Africa) |
|
Companies covered |
Twenty major players were covered, including |
This research report categorizes the tissue diagnostic market into the following segments and subsegments:
By Product
- Consumables
- Antibodies
- Kits
- Reagents
- Probes
- Instruments
- Slide Staining System
- Scanner
- Tissue Processing system
- Other instruments
By Technology
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Digital Pathology and Workflow Management
- Special Staining
By Disease
- Breast Cancer
- Gastric Cancer
- Lymphoma
- Prostate Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Other Diseases
By End User
- Hospitals
- Research Laboratories
- Pharmaceutical Companies
- Contract Research Organizations
- Other End Users
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Rest of the World
- Latin America
- Middle East and Africa
Recent Developments
- In 2019, Roche launched the VENTANA PD-L1 (SP142) Assay in CE (Conformitι Europιenne) markets.
- In 2019, Hologic received CE approval for ThinPrep Genesis Processor.
- In 2019, Roche entered into an agreement with GE Healthcare to develop an integrated digital diagnostics platform to improve oncology and critical care treatment.
Key Questions Addressed by the Report
- What are the various tissue diagnostic products and their respective market shares in the overall market?
- Where will these developments shape the industry in the mid-to-long term?
- What are the recent trends affecting the tissue diagnostic market?
- Who are the key players in the market, and how intense is the competition?
- What are the new trends and advancements in the tissue diagnostic market?
Frequently Asked Questions (FAQ):
Which is the leading type of Tissue Diagnostic Products?
The global tissue diagnostic market is segmented broadly into Instruments and Consumable. In 2017, consumables contributed largely to tissue diagnostic Market. This is primarily attributed to factors such as the rise in government and private funding in life sciences and cancer research, growing number of reagent rental agreements, and the application of innovative technologies. These factors have resulted in an increase in consumption of consumables in tissue diagnostic market.
Which is the leading end user for Tissue Diagnostic Product?
The end users of the tissue diagnostic market is segmented hospital, pharmaceutical companies, research laboratories, contract research organizations, and other end users (reference laboratories and academic research laboratories). In 2017, the hospitals segment has the largest share in global tissue diagnostics market. The large share of this segment can be attributed to the increasing number of patients visiting hospitals, rising number of in-house diagnostic procedures performed in hospitals, growing awareness regarding early diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals
Which is the leading type of technology used in tissue diagnostic market?
Tissue diagnostics market is categorized into four technology segmentsimmunohistochemistry (IHC), in situ hybridization (ISH), digital pathology and workflow, and special staining. The immunohistochemistry technology segment accounted for the largest share of the tissue diagnostics market in 2017. The large share of this segment can primarily be attributed to the increasing the number of deaths by chronic diseases. In addition, the growing demand for personalized medicine and higher growth in emerging countries.
Who are the key players operating in the tissue diagnostic market?
The global tissue diagnostic market is highly consolidated market. The prominent players operating in this market include Roche (Basel, Switzerland), Danaher (Washington), Thermo Fisher Scientific (Massachusetts), Abbott (Illnios).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 19)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 22)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 28)
4 PREMIUM INSIGHTS (Page No. - 32)
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE TISSUE DIAGNOSTIC MARKET
4.2 ASIA PACIFIC MARKET: BY DISEASE
4.3 TISSUE DIAGNOSTIC MARKET: GEOGRAPHIC SNAPSHOT
5 MARKET OVERVIEW (Page No. - 35)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of cancer
5.2.1.2 Growing healthcare expenditure
5.2.1.3 Developing infrastructure for cancer diagnosis
5.2.1.4 Recommendations for cancer screening
5.2.1.5 Availability of reimbursements
5.2.2 RESTRAINTS
5.2.2.1 High degree of consolidation
5.2.3 OPPORTUNITIES
5.2.3.1 Significant opportunities in BRICS countries
5.2.3.2 Growing demand for personalized medicines
5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory requirements
5.2.4.2 Lack of infrastructure and low awareness in middle- and low- income countries
5.2.4.3 Availability of refurbished products
5.2.4.4 Lack of skilled professionals
5.2.4.5 Product failures and recalls
5.2.5 TRENDS
5.2.5.1 Increasing number of reagent rental agreements
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 45)
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 ANTIBODIES
6.2.2 KITS
6.2.3 REAGENTS
6.2.4 PROBES
6.3 INSTRUMENTS
6.3.1 SLIDE-STAINING SYSTEMS
6.3.2 SCANNERS
6.3.3 TISSUE-PROCESSING SYSTEMS
6.3.4 OTHER INSTRUMENTS
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 55)
7.1 INTRODUCTION
7.2 IMMUNOHISTOCHEMISTRY (IHC)
7.3 IN SITU HYBRIDIZATION (ISH)
7.4 DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT
7.5 SPECIAL STAINING
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE (Page No. - 61)
8.1 INTRODUCTION
8.2 BREAST CANCER
8.3 GASTRIC CANCER
8.4 LYMPHOMA
8.5 PROSTATE CANCER
8.6 NON-SMALL CELL LUNG CANCER (NSCLC)
8.7 OTHER DISEASES
9 TISSUE DIAGNOSTICS MARKET, BY END USER (Page No. - 73)
9.1 INTRODUCTION
9.2 HOSPITALS
9.3 RESEARCH LABORATORIES
9.4 PHARMACEUTICAL COMPANIES
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.6 OTHER END USERS
10 TISSUE DIAGNOSTICS MARKET, BY REGION (Page No. - 78)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 US is expected to be dominant country-level market for tissue diagnostics
10.2.2 CANADA
10.2.2.1 High prevalence of cancer in Canada is expected to support market growth
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening
10.3.2 UK
10.3.2.1 Government initiatives to drive the growth in the UK
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support the market growth
10.3.4 ITALY
10.3.4.1 High incidence of cancer to support the market growth in Italy
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive the Spanish market
10.3.6 REST OF EUROPE (ROE)
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.1.1 Increasing healthcare expenditure
10.4.2 JAPAN
10.4.2.1 Advanced healthcare infrastructure to support market growth in Japan
10.4.3 INDIA
10.4.3.1 Expanding healthcare sector in the country to drive market growth
10.4.4 REST OF ASIA PACIFIC (ROAPAC)
10.5 REST OF THE WORLD (ROW)
10.5.1 LATIN AMERICA
10.5.1.1 Increasing number of cancer screening programs to support market growth
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to support market growth
11 COMPETITIVE LANDSCAPE (Page No. - 123)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, 2019
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT LAUNCHES (20172020)
11.3.2 PRODUCT APPROVALS (20172020)
11.3.3 PARTNERSHIPS AND COLLABORATIONS (20172020)
11.3.4 ACQUISITIONS (20172020)
11.4 COMPETITIVE LEADERSHIP MAPPING (2018)
11.4.1 VENDOR INCLUSION CRITERIA
11.4.2 VISIONARY LEADERS
11.4.3 DYNAMIC DIFFERENTIATORS
11.4.4 EMERGING COMPANIES
12 COMPANY PROFILES (Page No. - 129)
(Business overview, Products offered, Recent developments, MNM view)*
12.1 ROCHE
12.2 DANAHER
12.3 THERMO FISHER SCIENTIFIC
12.4 ABBOTT
12.5 AGILENT TECHNOLOGIES
12.6 MERCK KGAA
12.7 SAKURA FINETEK JAPAN
12.8 ABCAM
12.9 BECTON, DICKINSON AND COMPANY (BD)
12.10 BIO SB
12.11 BIOGENEX
12.12 CELL SIGNALING TECHNOLOGY
12.13 HISTO-LINE LABORATORIES
12.14 SLEE MEDICAL GMBH
12.15 AMOS SCIENTIFIC PTY LTD
12.16 JINHUA YIDI MEDICAL APPLIANCE CO.LTD
12.17 MEDITE GMBH
12.18 CELLPATH LTD
12.19 HOLOGIC, INC.
12.20 DIPATH S.P.A.
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 166)
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
LIST OF TABLES (127 TABLES)
TABLE 1 NUMBER OF PATHOLOGIST PER 100,000 POPULATION, BY COUNTRY, 2018
TABLE 2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 3 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 20182025 (USD MILLION)
TABLE 4 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 20182025 (USD MILLION)
TABLE 5 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 20182025 (USD MILLION)
TABLE 6 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 20182025 (USD MILLION)
TABLE 7 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 20182025 (USD MILLION)
TABLE 8 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 20182025 (USD MILLION)
TABLE 9 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 20182025 (USD MILLION)
TABLE 10 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 20182025 (USD MILLION)
TABLE 11 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 20182025 (USD MILLION)
TABLE 12 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 20182025 (USD MILLION)
TABLE 13 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 20182025 (USD MILLION)
TABLE 14 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 20182025 (USD MILLION)
TABLE 15 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 16 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 20182025 (USD MILLION)
TABLE 17 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 20182025 (USD MILLION)
TABLE 18 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT, BY REGION, 20182025 (USD MILLION)
TABLE 19 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 20182025 (USD MILLION)
TABLE 20 GLOBAL CANCER INCIDENCE, 2018 VS.2025
TABLE 21 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 20182025 (USD MILLION)
TABLE 22 BREAST CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 23 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 20182025 (USD MILLION)
TABLE 24 STOMACH CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 25 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 20182025 (USD MILLION)
TABLE 26 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 27 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 28 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 20182025 (USD MILLION)
TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 30 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 20182025 (USD MILLION)
TABLE 31 LUNG CANCER INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 32 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 20182025 (USD MILLION)
TABLE 33 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 20182025 (USD MILLION)
TABLE 34 TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 35 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 20182025 (USD MILLION)
TABLE 36 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 20182025 (USD MILLION)
TABLE 37 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 20182025 (USD MILLION)
TABLE 38 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 20182025 (USD MILLION)
TABLE 39 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 20182025 (USD MILLION)
TABLE 40 TISSUE DIAGNOSTICS MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 41 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 42 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 43 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 20182025 (USD MILLION)
TABLE 44 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 20182025 (USD MILLION)
TABLE 45 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 20182025 (USD MILLION)
TABLE 46 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 47 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 48 US CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 49 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 50 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 51 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 52 CANADA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 53 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 54 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 55 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 56 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 57 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 58 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 20182025 (USD MILLION)
TABLE 59 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 20182025 (USD MILLION)
TABLE 60 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 20182025 (USD MILLION)
TABLE 61 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 62 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 63 GERMANY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 64 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 65 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 66 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 67 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 68 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 69 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 70 FRANCE CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 71 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 72 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 73 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 74 ITALY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 75 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 76 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 77 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 78 SPAIN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 79 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 80 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 81 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 82 KEY REST OF EUROPEAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025
TABLE 83 KEY REST OF EUROPEAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025
TABLE 84 KEY REST OF EUROPEAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025
TABLE 85 ROE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 86 ROE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 87 ROE: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 88 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 89 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 90 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 20182025 (USD MILLION)
TABLE 91 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 20182025 (USD MILLION)
TABLE 92 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 20182025 (USD MILLION)
TABLE 93 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 94 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 95 CHINA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 96 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 97 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 98 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 99 JAPAN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 100 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 101 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 102 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 103 INDIA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 104 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 105 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 106 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 107 INCIDENCE OF CANCER IN ROPAC
TABLE 108 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 109 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 110 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 111 ROW: TISSUE DIAGNOSTICS MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 112 ROW: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 113 ROW: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 20182025 (USD MILLION)
TABLE 114 ROW: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 20182025 (USD MILLION)
TABLE 115 ROW: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 20182025 (USD MILLION)
TABLE 116 ROW: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 117 ROW: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 118 KEY LATIN AMERICAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025
TABLE 119 KEY LATIN AMERICAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025
TABLE 120 KEY LATIN AMERICAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025
TABLE 121 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 122 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 123 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
TABLE 124 AFRICA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 125 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 126 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 20182025 (USD MILLION)
TABLE 127 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 20182025 (USD MILLION)
LIST OF FIGURES (38 FIGURES)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION FROM THE PARENT MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 TISSUE DIAGNOSTIC MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 7 TISSUE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
FIGURE 8 TISSUE DIAGNOSTIC MARKET, BY DISEASE, 2020 VS. 2025 (USD MILLION)
FIGURE 9 TISSUE DIAGNOSTIC MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
FIGURE 10 GEOGRAPHIC SNAPSHOT OF THE GLOBAL TISSUE DIAGNOSTIC MARKET
FIGURE 11 RISING INCIDENCE OF CANCER TO DRIVE THE GROWTH OF THE TISSUE DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
FIGURE 12 GASTRIC CANCER SEGMENT DOMINATED THE APAC MARKET IN 2019
FIGURE 13 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 14 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES, AND TRENDS
FIGURE 15 CURRENT HEALTH EXPENDITURE PER CAPITA
FIGURE 16 CURRENT HEALTH EXPENDITURE (% OF GDP)
FIGURE 17 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 20122016
FIGURE 18 NUMBER OF ARTICLES RELATED TO TISSUE DIAGNOSTICS PUBLISHED ON PUBMED (20102019)
FIGURE 19 ARTICLES PUBLISHED ON CANCER TISSUE DIAGNOSTICS, 20102019
FIGURE 20 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 20102019
FIGURE 21 ARTICLES PUBLISHED ON GASTRIC CANCER TISSUE DIAGNOSTICS, 20102019
FIGURE 22 ARTICLES PUBLISHED ON LYMPHOMA TISSUE DIAGNOSTICS, 20102018
FIGURE 23 ARTICLES PUBLISHED ON PROSTATE CANCER TISSUE DIAGNOSTICS, 20102018
FIGURE 24 ARTICLES PUBLISHED ON NON-SMALL CELL LUNG CANCER TISSUE DIAGNOSTICS, 20102019
FIGURE 25 TISSUE DIAGNOSTICS MARKET IN NORTH AMERICA: SNAPSHOT
FIGURE 26 TISSUE DIAGNOSTICS MARKET IN ASIA PACIFIC: SNAPSHOT
FIGURE 27 PRODUCT LAUNCHES-THE MOST ADOPTED GROWTH STRATEGY FROM 2017 TO 2020
FIGURE 28 SHARES OF TOP COMPANIES IN THE GLOBAL TISSUE DIAGNOSTIC MARKET (2019)
FIGURE 29 TISSUE DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING
FIGURE 30 ROCHE: COMPANY SNAPSHOT (2019)
FIGURE 31 DANAHER: COMPANY SNAPSHOT (2019)
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2019)
FIGURE 34 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2019)
FIGURE 35 MERCK: COMPANY SNAPSHOT (2019)
FIGURE 36 ABCAM: COMPANY SNAPSHOT (2019)
FIGURE 37 BD: COMPANY SNAPSHOT (2019)
FIGURE 38 HOLOGIC, INC: COMPANY SNAPSHOT (2019)
The study involved four major activities in estimating the current size of the tissue diagnostic market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Then, both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
The secondary sources referred to for research study on the tissue diagnostic market include publications from government sources such as white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations were referred to identify and collect information for this study.
Primary Research
The tissue diagnostic market comprises several stakeholders, such as tissue diagnostic manufacturers and distributors. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the tissue diagnostic market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research.
- The industry's supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall tissue diagnostic market sizeusing the market size estimation processes as explained abovethe market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the tissue diagnostic industry.
Report Objectives
- To define, describe, segment, and forecast the tissue diagnostics market on the basis of products, technologies, diseases, end users, and regions
- To forecast the revenue of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
- To identify the micromarkets with respect to drivers, restraints, industry-specific challenges, opportunities, and trends affecting the growth of the market
- To strategically analyze the market segments and subsegments with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players and comprehensively analyze their market shares and core competencies3 in terms of market developments and growth strategies
- To track and analyze competitive developments such as partnerships, agreements, collaborations, and joint ventures; mergers and acquisitions; product launches; and research and development activities in the tissue diagnostics market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company's specific needs. The following customization options are available for the tissue diagnostic market report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
- Company Information: Detailed analysis and profiling of additional market players (Up to 5)
Get in-depth analysis of the COVID-19 impact on the Tissue Diagnostics Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Tissue Diagnostics Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Tissue Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Tissue Diagnostics Market